Adjuvant Therapy of Colon Cancer: Current Status and Future Developments

Por Morse, Michael A.
Publicado em 2005

Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy

Por Morse, Michael A., Hochster, Howard, Benson, Al
Publicado no Oncologist (2019)

Letters to the Editor

Por Clavien, Pierre- A., Selzner, Markus, Morse, Michael A.
Publicado em 1999

Novel Recombinant Alphaviral and Adenoviral Vectors for Cancer Immunotherapy

Por Osada, Takuya, Morse, Michael A., Hobeika, Amy, Lyerly, H. Kim
Publicado em 2012

Treatment of Recurrent Intracranial Hemangiopericytoma with SRC-Related Tyrosine Kinase Targeted Therapy: A Case Report

Por Peters, Katherine B., McLendon, Roger, Morse, Michael A., Vredenburgh, James J.
Publicado em 2010

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient With Treatment Refractory Metastatic Colorectal Cancer

Por Jia, Jingquan, Morse, Michael A., Nagy, Rebecca J., Lanman, Richard B., Strickler, John H.
Publicado no Front Oncol (2018)

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer

Por Chawla, Sant P., Bruckner, Howard, Morse, Michael A., Assudani, Nupur, Hall, Frederick L., Gordon, Erlinda M.
Publicado no Mol Ther Oncolytics (2018)

Molecular Basis for Cell Tropism of CXCR4-Dependent Human Immunodeficiency Virus Type 1 Isolates

Por Tokunaga, Kenzo, Greenberg, Michael L., Morse, Michael A., Cumming, R. Ian, Lyerly, H. Kim, Cullen, Bryan R.
Publicado em 2001

Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs

Por Hu, Zhenlin, Yang, Xiao Yi, Liu, Yunbo, Morse, Michael A., Lyerly, H. Kim, Clay, Timothy M., Zhong, Pei
Publicado em 2005

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines

Por Morse, Michael A., Hobeika, Amy C., Osada, Takuya, Serra, Delila, Niedzwiecki, Donna, Lyerly, H. Kim, Clay, Timothy M.
Publicado em 2008

POLYCLONAL IMMUNE RESPONSES TO ANTIGENS ASSOCIATED WITH CANCER SIGNALING PATHWAYS AND NEW STRATEGIES TO ENHANCE CANCER VACCINES

Por Clay, Timothy M., Osada, Takuya, Hartman, Zachary C., Hobeika, Amy, Devi, Gayathri, Morse, Michael A., Lyerly, H. Kim
Publicado em 2011

Phase I study of alphaviral vector (AVX701) in colorectal cancer patients: comparison of immune responses in stage III and stage IV patients

Por Morse, Michael A, Hobeika, Amy, Gwin, William, Osada, Takuya, Gelles, Jonathan, Rushing, Christel, Niedzwiecki, Donna, Lyerly, H Kim
Publicado no J Immunother Cancer (2015)

Longitudinal Patterns of Chemotherapy Use in Metastatic Colorectal Cancer

Por Zafar, S. Yousuf, Marcello, Jennifer E., Wheeler, Jane L., Rowe, Krista L., Morse, Michael A., Herndon, James E., Abernethy, Amy P.
Publicado em 2009

Enhancement of Anti-Tumor Immunity Through Local Modulation of CTLA-4 and GITR by Dendritic Cells

Por Pruitt, Scott K., Boczkowski, David, de Rosa, Nicole, Haley, N. Rebecca, Morse, Michael A., Tyler, Douglas S., Dannull, Jens, Nair, Smita
Publicado em 2011

Perhexiline promotes HER3 ablation through receptor internalization and inhibits tumor growth

Por Ren, Xiu-Rong, Wang, Jiangbo, Osada, Takuya, Mook, Robert A, Morse, Michael A, Barak, Larry S, Lyerly, Herbert Kim, Chen, Wei
Publicado no Breast Cancer Res (2015)

Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma

Por Jiang, Betty S., Beasley, Georgia M., Speicher, Paul J., Mosca, Paul J., Morse, Michael A., Hanks, Brent, Salama, April, Tyler, Douglas S.
Publicado no Ann Surg Oncol (2014)

Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer

Por Huang, Lefu, Qiao, Guoliang, Morse, Michael A., Wang, Xiaoli, Zhou, Xinna, Wu, Jiangping, Hobeika, Amy, Ren, Jun, Lyerly, Herbert K.
Publicado no Oncol Lett (2019)

Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab for Advanced Hepatocellular Carcinoma

Por Sanoff, Hanna K., Bernard, Stephen, Goldberg, Richard M., Morse, Michael A., Garcia, Reynaldo, Woods, Lynna, Moore, Dominic T., O'Neil, Bert H.
Publicado em 2011

High dose interleukin-2 registry, PROCLAIM™; higher center-specific IL-2 dose density correlates with higher response rates

Por Wong, Michael K, Daniels, Gregory A, Kaufman, Howard L, McDermott, David F, Morse, Michael A, Aung, Sandra, Lowder, James N
Publicado em 2013

Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes

Por Wong, Michael K, Kaufman, Howard L, Daniels, Gregory A, McDermott, David F, Aung, Sandra, Lowder, James N, Morse, Michael A
Publicado em 2014